Humanized liver mice model market to value over USD 115 Million by 2029 end and register a CAGR of over 5.5% from 2019 to 2029.
Humanized mice models are mice that perform human functioning due to the presence of similar genes. Humanized mice models can be attained, through gene modification and replacement.
Extensive research efforts are focused on developing efficient and new humanized liver mice models. Initially, using simple immune-deficient methods were employed, and mice were implanted with human liver cells or hepatic cancer cells. However, the results were not as desired and consistent. The unreliability of the process led to the discovery of immune-deficient mice that naturally annihilate the mice liver allowing the human liver cells to grow and replace to form stable humanized liver mice models. For instance, a number of studies are exploring the use of PPARalfa and AFC8-based mice models for the development of a humanized liver mice model. Another humanized liver mice model known as the hPXR/CAR/CYP3A4/ 2D6/2C9 mouse has 33 mouse genes replaced with human genetic counterparts. Furthermore, with the improvement in medical science and genetic technology, the scope of developing new genetically engineered humanized liver mice models has widened. The invention of CRISPR technology is one such instance.
The approval of numerous liver disease-associated drugs by the FDA has also promoted the growth of the market and encouraged research and development. The high expenses of humanized liver mice are projected to restrain the growth of the market. For instance, the immune-deficient mice used for liver studies through grafting are available in the range of US$ 140–500, whereas chimeric humanized liver mice with 75–90% of human hepatocyte replacement, cost about US$ 2500–3500. In addition, since these are specifically genetically modified species, the shipping costs are also significantly higher along with the special containers and facility provided during the transportation, these overheads invariably increase the overheads.
Replace, reduce and refine is the policy followed in animal studies. It provides a framework for humane research. Replacement of animal models allows the use of alternatives such as 2D & 3D cell lines and is recommended to reduce the number of animals. The aim behind this is to minimize animal suffering without compromising on the statistics of the experiment or research.
Request a Sample Report @ https://www.futurewiseresearch.com/request-sample.aspx?id=254&page=requestsample
By Application
● Pharmacokinetics Studies
● In-vivo Liver Toxicity Testing
● Drug Metabolism Studies
● Others
By Model
● uPA-SCID
● FRG KO Mice
● TK-NOG Mice
● Other Models
By End User
● Pharmaceutical Companies
● Biotechnology Companies
● Contract Research Organizations (CRO’s)
● Academic & Research Institutes
By Region:
● Europe
● North America
● APAC
● Latin America
● Rest of World
The market of North America garners the maximum revenue and is expected to grow at the highest CAGR during the forecast period.
Purchase a Copy of this Premium Research Report & Ask for Discount: https://www.futurewiseresearch.com/request-sample.aspx?id=254&page=askfordiscount
Competitive Landscape:
● Tier 1 players- established companies in the market with a major market share
● Tier 2 players
● Emerging players which are growing rapidly
● New Entrants
Major market influencers include Yecuris Corporation, PhoenixBio Group, Beijing Vitalstar Biotechnology Co. Ltd., Hera BioLabs, Taconic Biosciences, Inc., University of Massachusetts Medical School, Oncodesign, University of Nebraska Medical Center and Jackson Laboratory.
FutureWise Key Takeaways
● Growth prospects
● SWOT analysis
● Key trends
● Key data points affecting market growth
Objectives of the Study:
● To provide an exhaustive analysis on the humanized liver mice model based on application, model, end user and region
● To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
● To evaluate and forecast micro-markets and overall market
● To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
● To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
● Profiling of companies to evaluate their market shares, strategies, financials and core competencies

Table of Contents
1. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
2. Executive Summary
1.1. Market Overview
1.2. Market Analysis
3. Humanized Liver Mice Model Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Trends
5. Historical Market Value (US$ Mn) Trend Analysis By Model, 2014–2019
5.4.1. uPA-SCID
5.4.2. FRG KO Mice
5.4.3. TK-NOG Mice
5.4.4. Other Models
5.5. Market Value (US$ Mn) Forecast By Model, 2019–2029
6. Historical Market Value (US$ Mn) Trend Analysis By Application, 2014–2019
6.6.1. Pharmacokinetics Studies
6.6.2. In-vivo Liver Toxicity Testing
6.6.3. Drug Metabolism Studies
6.6.4. Others
6.7. Market Value (US$ Mn) Forecast By Application, 2019–2029
7. Historical Market Value (US$ Mn) Trend Analysis By End User, 2014–2019
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations (CRO’s)
• Academic & Research Institutes
7.1 Market Value (US$ Mn) Forecast By End User, 2019–2029
8. North America Humanized Liver Mice Model Market Analysis 2014–2018 and Forecast 2019–2029
Introduction
Historical Market Value (US$ Mn) Trend Analysis By Country, 2014–2018
• U.S.
• Canada
Market Value (US$ Mn) Forecast By Country, 2019–2029
8. Latin America Humanized Liver Mice Model Market Analysis 2014–2018 and Forecast 2019–2029
8.1. Introduction
8.2. Historical Market Value (US$ Mn) Trend Analysis By Country, 2014–2018
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
9. Europe Humanized Liver Mice Model Market Analysis 2014–2018 and Forecast 2019–2029
9.1. Introduction
9.2. Historical Market Value (US$ Mn) Trend Analysis By Country, 2014–2018
9.2.1. U.K.
9.2.2. Germany
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Market Value (US$ Mn) Forecast By Country, 2019–2029
10. Asia Pacific Excluding China Humanized Liver Mice Model Market Analysis 2014–2018 and Forecast 2019–2029
10.1. Introduction
10.2. Historical Market Value (US$ Mn) Trend Analysis By Country, 2014–2018
10.2.1. Japan
10.2.2. India
10.2.3. Australia and New Zealand
10.2.4. South Korea
10.2.5. ASEAN
10.2.6. Rest of Asia Pacific
10.3. Market Value (US$ Mn) Forecast By Country, 2019–2029
11. China Humanized Liver Mice Model Market Analysis 2014–2018 and Forecast 2019–2029
11.1. Introduction
11.2. Historical Market Value (US$ Mn) Trend Analysis By Model, 2014–2018
11.2.1. uPA-SCID
11.2.2. FRG KO Mice
11.2.3. TK-NOG Mice
11.2.4. Other Models
11.3. Market Value (US$ Mn) Forecast By Model, 2019–2029
12. Middle East & Africa Humanized Liver Mice Model Market Analysis 2014–2018 and Forecast 2019–2029
12.1. Introduction
12.2. Historical Market Value (US$ Mn) Trend Analysis By Country, 2014–2018
12.2.1. GCC Countries
12.2.2. South Africa
12.2.3. Rest of MEA
12.3. Market Value (US$ Mn) Forecast By Country, 2019–2029
13. Competition Analysis
• Hera BioLabs
• Taconic Biosciences, Inc.
• Beijing Vitalstar Biotechnology Co., Ltd.
• Yecuris Corporation
• PhoenixBio Group
• In-Vivo Science Inc.
• The Jackson Laboratory
• University of Massachusetts Medical School(Mueller Lab)
• Oncodesign
• University of Nebraska Medical Center
Inquire further details about this report at: [email protected]
About FutureWise Research:
We specialise in high-growth niche markets, assuring flexibility, agility and customised solutions for our clients. Through in-depth market insights and consultancy, we present our clients with the tools they need to be at the forefront of their industry – a position secured for far more than the near future.
Contact Us:
Company Name: FutureWise Research
Contact Person: Vinay Thaploo
Email: [email protected]
Phone: +44 141 628 9353 / +1 970 279 4295
City: Leeds
Country: United Kingdom
Website: www.futurewiseresearch.com